Paclitaxel: In cancer patients receiving TYKERB and the CYP2C8 substrate paclitaxel, 24-hour systemic exposure (AUC) of paclitaxel was increased 23%. This increase in paclitaxel exposure may have been underestimated from the in vivo evaluation due to study design limitations. 7.2 Drugs that ...
We are writing to inform you that the FDA is evaluating recent information regarding the potential for increased long-term mortality after use of paclitaxel-coated balloons and paclitaxel-eluting stents to treat peripheral arterial disease (PAD) in the femoropopliteal artery. A recent meta-analysis of...
The US Food and Drug Administration (FDA) is giving the green light for clinical studies of paclitaxel-coated balloons and stents to continue after evidence of a late mortality signal in patients receiving the devices forperipheral artery disease(PAD) brought trials to a virtual halt worldwide. I...
The US Food and Drug Administration (FDA) today approved nanoparticle albumin-bound (nab)-paclitaxel (Abraxane, Celgene), in combination with gemcitabine, for the first-line treatment of metastatic pancreatic cancer. The drug is specifically approved for adenocarcinoma of the pancreas, a subtype that...
The National Comprehensive Cancer Network (NCCN) guidelines for endometrial carcinoma have classified dostarlimab plus carboplatin and paclitaxel as a category 1 recommendation for stage III/IV tumors, particularly for “stage IIIA, IIIB, or IIIC1 with measurable disease, stage IIIC1 with carcino...
in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy (1.1) ? in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adj...
1.2 Breast Cancer Gemzar in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. 1.3 Non-Small Cell Lung Cancer Gemzar is ...
抑郁症治疗实用指南(英文版:Practice_Guideline_for_the_Treatment_of_Patients_With_Depression) 热度: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents 热度: Preclinical development of a novel triptolide prodrug for cancer treatment ...
et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 44–59 (2020). Article CAS...
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor ...